Secondary end point as determined by MRI evaluation for the intention-to-treat population*
| Analysis | IRR (95% CI) | P value |
| Number of T1-enhancing lesions (month 30) | 0.29 (0.11 to 0.76) | 0.011 |
| New/enlarging T2-hyperintense lesions at month 30 versus baseline | 0.49 (0.38 to 0.62) | <0.0001 |
*All analyses adjusted for: age, sex, years of diagnosis, baseline Expanded Disability Status Scale, relapses during normalisation.
IRR, Incidence rate ratio.